Electronic Genome Mapping Enables High-Resolution Cytogenomic Profiling of Hematologic Malignancies: A Proof-of-Principle Study
Mondal, A. K., Vashisht, V., Zhang, Y., Gallagher, M. D., Shukor, S., Diaz, M., Vashisht, A., Chaubey, A., et al.
hematology
Quick verdict
A five-sample, vendor-affiliated pilot: Nabsys EGM matches SOC and OGM on known enriched abnormalities — feasibility shown, validation not yet.
Summary
This preprint reports a proof-of-principle evaluation of electronic genome mapping (EGM) on the Nabsys OhmX platform as a potential single-assay alternative to karyotyping, FISH, and chromosomal microarray in hematologic malignancies. Five previously characterized bone marrow aspirates (four AML, one CML) were mapped at a stated target of 300x or greater, analyzed with the proprietary Navigator SV Discover (v1.0.0) and CNV (v0.9.0) pipelines, and compared event-by-event with archived standard-of-care (SOC) and optical genome mapping (OGM) results. EGM reproduced all six SOC-reported abnormalities (two BCR::ABL1 translocations, trisomy 4, trisomy 21, monosomy 7) and all nine OGM calls, refining t(9;22) breakpoints to base-pair coordinates, resolving a del(20q) into an intrachromosomal fusion fus(20;20)(q11.21;q13.12), and detecting a ~1.8 Mb 7q22.1 loss and a KMT2A insertion missed by KT/FISH. The authors claim 100% concordance. Key limitations: the cohort is tiny and deliberately enriched for known pathogenic events, so sensitivity, specificity, and false-positive rates cannot be estimated; no blinded analysis is stated; four co-authors are Nabsys employees; two specimens deviated from recommended QC cutoffs (AUG-668 coverage 292x, AUG-679 label FNR 11.2%) while the abstract states all five passed QC; copy-number estimates (e.g., CN 1.46 for -7, 2.28 for +4) deviate from expected integers without discussion; and data are available only upon request. This is a feasibility signal, not a validation.
Review complete
Assessment at a glance
5
risk flags identified
● high 1
● medium 3
● low 1
4 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- EGM on the Nabsys OhmX platform detected all six standard-of-care cytogenetic abnormalities and all nine OGM calls across five myeloid malignancy specimens, yielding 100% event-level concordance.
- EGM provides breakpoint-level resolution beyond karyotype and FISH, refining t(9;22) to base-pair coordinates and resolving a del(20q) into the intrachromosomal fusion fus(20;20)(q11.21;q13.12).
- Genome-wide EGM analysis additionally detected a ~1.8 Mb 7q22.1 loss (~45 genes, CUX1) and a KMT2A insertion that karyotyping and FISH missed, both matching OGM.
- These findings justify larger prospective studies across more subtypes toward establishing EGM as a first-line genome-wide cytogenomic assay.
Strengths
First documented EGM evaluation in hematologic malignancies against a three-way comparator
The introduction states EGM performance 'has not yet been described in a peer-reviewed cohort'; Table 1 provides per-sample, GRCh38 event-level comparisons across KT, FISH, OGM, and EGM for all five specimens, a genuinely novel instrument-level demonstration.
Resolution beyond standard-of-care is concretely demonstrated
Fig 2 resolves the KT/FISH del(20q) of AUG-664 into fus(20;20)(q11.21;q13.12) with junction coordinates chr20:32,722,804–45,869,827; Fig 3 shows two independent BCR::ABL1 breakpoint pairs (AUG-679: chr22:23,224,581/chr9:130,714,817; AUG-667: chr22:23,289,565/chr9:130,797,020); both EGM and OGM found a ~1.8 Mb 7q22.1 loss and an ~8 kb KMT2A insertion that KT/FISH missed.
QC deviations are disclosed rather than hidden
Honest scoping of conclusions
Weaknesses
Study design cannot support any performance estimate
No blinding statement despite vendor authors performing the analysis
Internal inconsistency between abstract and results on QC
Copy-number point estimates deviate from integers without discussion
Low reproducibility and unverified KMT2A call
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Scope & Claims
This medRxiv preprint (2026-09-17) presents the first documented application of electronic genome mapping (EGM) — the Nabsys OhmX electronic single-molecule readout — to hematologic malignancy specimens. Five previously characterized bone marrow aspirates (four AML, one CML) from Augusta University (IRB #611298) were remapped and compared event-by-event against archived karyotyping (KT), FISH, and optical genome mapping (OGM) reports. The paper claims: (1) 100% event-level concordance — 6/6 SOC abnormalities (two t(9;22)/BCR::ABL1 rearrangements, trisomy 4, trisomy 21, monosomy 7) and 9/9 OGM calls; (2) breakpoint-level resolution beyond karyotype, with base-pair BCR::ABL1 coordinates and reinterpretation of a del(20q) as fus(20;20)(q11.21;q13.12); (3) detection of a ~1.8 Mb 7q22.1 loss (~45 genes, CUX1) and a KMT2A insertion missed by KT/FISH. The authors explicitly frame the work as proof-of-principle and defer any first-line role to larger studies — appropriate framing that the headline concordance number nonetheless strains against.
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 4 strengths & 5 weaknesses, analyzed in detail
- 5 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
What is electronic genome mapping (EGM) and how is it different from optical genome mapping (OGM)?
EGM, run on the Nabsys OhmX platform, detects sequence-specific labels along long individual DNA molecules with an electronic single-molecule detector, whereas OGM uses fluorescence imaging. Both assemble labeled molecules into genome-wide contigs aligned to a reference to find structural variants and copy-number changes. This preprint is one of the first comparisons of EGM against OGM and standard cytogenetics in leukemia samples.
Did EGM find everything that karyotype and FISH found in this study?
In all five samples, EGM detected every abnormality reported by standard-of-care testing: two BCR::ABL1 translocations, trisomy 4, trisomy 21, and monosomy 7, and it also matched all nine optical genome mapping calls. Because the five samples were chosen precisely because they carried known abnormalities, this demonstrates feasibility, not validated sensitivity.
What did EGM see that karyotyping and FISH missed?
A ~1.8 Mb deletion at 7q22.1 (spanning roughly 45 genes, with CUX1 the cancer-associated one) and an ~8 kb insertion within KMT2A, both also seen by OGM. It also refined the t(9;22) breakpoints to base-pair coordinates and reinterpreted one sample's apparent del(20q) as an intrachromosomal fusion, fus(20;20)(q11.21;q13.12).
Can this study justify replacing karyotype and FISH with EGM in clinical testing?
No. Five vendor-enriched samples cannot estimate sensitivity, specificity, or false-positive rates, the analysis was not stated to be blinded, and two samples fell outside recommended QC thresholds. The authors themselves call for larger prospective studies before any first-line clinical use.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- Figures 1–3 are available only as extracted captions; the actual plots, molecule-level evidence displays, and Figure 2/3 imagery could not be inspected.
- Label false-negative rates per specimen were explicitly withheld from the paper ('data not shown'), limiting QC evaluation.
- The supplied metadata abstract was truncated mid-sentence, though the full abstract appears in the extracted body text; Table 1 formatting was flattened during extraction.
- The abstract contains two overlapping background paragraphs, suggesting the preprint retains draft-stage text; review is based on the preprint alone with no supplementary files.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.